A Life Sciences Tools · Diagnostics · Lab instruments · Recurring revenue · Thesis updated June 12, 2026

Lab recovery is real, but not even

Q2 revenue rose 10%, helped by about 6% core growth and favorable currency.
Pharma, diagnostics, and chemical and advanced materials demand are carrying the recovery.
Agilent CrossLab gives the company steadier service and consumables sales from a large installed base.
Academia and government customers remain the clearest demand weak spot.
The pending Biocare deal adds a new diagnostics growth path, but integration still has to go right.

01 Running thesis

Recovery with one weak lane

Agilent looks better than it did earlier in the cycle. In Q2 FY2026, revenue was $1.835 billion, up 10% from last year. Core growth, which strips out currency effects and other items, was about 6%. That is near the top of management's full-year 4% to 6% core growth range.

The bull case is that the lab spending recovery is turning into real orders. Pharma and biotech demand keeps improving. Chemical and advanced materials demand is also strong, helped by areas like semiconductor-related testing. Applied Markets grew 14% in Q2, and Life Sciences and Diagnostics Markets grew 12%.

The bear case is not broken. Currency added 4 percentage points to reported Q2 revenue growth, so the headline number was stronger than the core business alone. Academia and government spending is still weak, especially where U.S. federal funding affects lab equipment budgets. Agilent also faces a higher tax rate in FY2026, which can hold back reported EPS even if operations improve.

The Biocare acquisition is the new swing factor. Agilent agreed to buy Biocare for about $950 million in cash. If it closes and fits well, it should deepen Agilent's diagnostics and clinical tools portfolio. If it distracts management or costs more to integrate than expected, it could slow the recovery story.

Jun 2026▲Q2 showed faster core growth near the high end of full-year guidance. Agilent also announced the pending Biocare acquisition, adding a new diagnostics catalyst.

Mar 2026→The Q1 10-Q confirmed the same thesis from earnings. Revenue growth was healthy, but no new risk or strategy change moved the view.

Feb 2026→Q1 core growth of 4.4% matched the full-year plan. CAM demand surprised to the upside, while academia and government demand was weaker than expected.

Dec 2025→The FY2025 10-K confirmed the broad recovery and did not add a major new business shift. Tariff and macro risks stayed part of the watch list.

Nov 2025▲Q4 ended FY2025 with 7.2% core growth and strong pharma and biotech demand. The offset was a higher FY2026 tax headwind that limited the earnings upside.

Aug 2025→The Q3 10-Q backed up the broadening recovery but also confirmed margin pressure from tariffs, shipping, and mix. New international tax risks were added to the risk list.

Aug 2025▲Q3 shifted the view from a split recovery to broader acceleration. Applied Markets turned positive, but stronger growth came with margin and tariff execution risk.

02 Business model

Sell the lab, then service it

Agilent makes money by selling lab instruments, software, services, and consumables. A customer may buy a chromatography or mass spectrometry machine first. After that, the lab still needs columns, parts, repairs, training, compliance work, and software.

That installed base matters. Agilent CrossLab sells services and consumables across many customer types, and much of the consumables and services portfolio is vendor neutral. That means Agilent can help a lab even when the lab uses some equipment made by another company.

The model can break when customers delay big equipment buys. Universities, government labs, and some funded research groups can stretch old instruments instead of replacing them. Pharma and chemical customers can also cut capital spending if their own markets slow.

Agilent's stronger financial health helps it stay patient. The company had cash and cash equivalents of $1.807 billion at April 30, 2026. It also had no borrowings outstanding under its main credit facility, incremental revolving facility, or U.S. commercial paper program at that date.

03 Product portfolio

Tools across the lab bench

Growth engine

Liquid chromatography and mass spectrometry

These tools help labs separate, identify, and measure chemicals and biological samples. Q2 growth in Life Sciences was led in part by liquid chromatography and liquid chromatography mass spectrometry demand.

Growth engine

Gas chromatography and applied instruments

These systems test chemicals, food, water, fuels, and materials. Applied Markets grew 14% in Q2, with strong demand in chemical and advanced materials and environmental and forensics markets.

Cash cow

Agilent CrossLab services and consumables

CrossLab sells repairs, maintenance, training, compliance support, software, and lab supplies. It grew 6% in Q2 and gives Agilent a more repeatable revenue stream than instruments alone.

Growth engine

Diagnostics and pathology solutions

This group supports cancer diagnostics, tissue staining, companion diagnostics, genomics, and clinical workflows. Diagnostics and clinical markets were a strong source of Q2 growth.

Option

Agilent Advanced Therapeutics

This business makes active pharmaceutical ingredients for nucleic acid-based drugs and related biomanufacturing services. It offers upside if demand for these newer drug types keeps expanding.

Option

Biocare

Biocare is a pending acquisition in clinical and research solutions. Agilent plans to include it in Life Sciences and Diagnostics Markets after close.

04 Business segments

CrossLab is the largest slice

Life Sciences and Diagnostics Markets40%growing fast

Agilent CrossLab41%modest

Applied Markets19%growing fast

Segment mix uses Q2 FY2026 revenue for the three months ended April 30, 2026. CrossLab was the largest segment in the quarter, but all three segments grew year over year.

05 Risk factors

What could trip the recovery

Academia and government keep cutting equipment

Medium impact · High odds

Agilent says academia and government revenue declined again in Q2. These customers may use funding to keep labs running instead of buying new capital equipment. If this lasts, it can offset some of the pharma and chemical recovery.

We watchLook for management comments on academia and government revenue growth or stabilization each quarter.

Currency makes growth look better than demand

Medium impact · Medium odds

Reported Q2 revenue growth was 10%, but currency added 4 percentage points. If foreign exchange stops helping, reported growth could slow even if core demand stays steady. That would make the recovery look less strong on the income statement.

We watchCompare reported revenue growth with core growth and the currency impact each quarter.

Tax rules pressure EPS

Medium impact · High odds

Agilent has guided for a higher FY2026 tax rate because of new international tax rules. The internal view expects a 14.5% tax rate and about a three percentage point headwind to EPS growth. This can make earnings growth look weaker than revenue growth.

We watchTrack the effective tax rate, guidance for tax expense, and any updates on OECD Pillar Two or U.S. OBBBA effects.

Tariffs and trade costs return

Medium impact · Medium odds

Tariffs hurt costs in FY2025, and the company later raised its expected net tariff cost for that year to about $20 million. Agilent says it has mitigated the cost impact in the first half of FY2026, but trade rules remain fluid. New tariffs or delayed refunds could pressure margins again.

We watchWatch gross margin, tariff cost comments, and any U.S. Customs refund updates.

Biocare integration disappoints

Medium impact · Medium odds

Agilent agreed to buy Biocare for about $950 million in cash. The deal adds clinical and research solutions, but it still needs legal and regulatory approvals and then integration. A slow close or messy integration would weaken a key growth catalyst.

We watchMonitor deal close timing, integration costs, and diagnostics and clinical revenue after Biocare is included.

06 Quick answers

In one breath

What does Agilent Technologies do?

Agilent sells tools used by labs to test chemicals, drugs, biological samples, food, water, and materials. Its products include instruments, software, services, consumables, diagnostics tools, and genomics solutions.

Why is Agilent tied to pharma and biotech spending?

Drug companies use Agilent systems to develop, test, and manufacture therapies. When pharma and biotech customers spend more on lab work and equipment, Agilent usually benefits.

Why does Agilent CrossLab matter?

CrossLab sells services and consumables after instruments are already in the lab. That can make revenue steadier because labs still need repairs, parts, maintenance, and compliance support.

What is the biggest near-term risk for Agilent?

The main demand risk is weak academia and government spending. The main earnings risk is that currency, tax, tariffs, or acquisition costs hide the improvement in core demand.